Recombinant adenoviruses for gene therapy in cancers

Details Recombinant adenoviruses for gene therapy in cancers Recombinant adenoviruses for gene therapy in cancers

2006-04-25

2006-04-25

Nguyen, Dave T. (Department: 1632)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C435S069100, C435S320100, C435S091400

Reissue Patent

active

RE039078

ABSTRACT:
The invention concerns recombinant viruses comprising a heterologous DNA sequence under the control of expression signals specifically active in tumor cells, and their preparation and use in the treatment and prevention of cancers.

REFERENCES:
patent: 4939088 (1990-07-01), Young et al.
patent: 5194601 (1993-03-01), Sugden et al.
patent: 5631236 (1997-05-01), Woo et al.
patent: 5672344 (1997-09-01), Kelley et al.
patent: WO 92/05262 (1992-04-01), None
patent: WO 93/19191 (1993-03-01), None
patent: WO 93/19191 (1993-09-01), None
Stefan Karlsson (1991) Blood, vol. 78, No. 10: pp. 2481-2492.
Dong et al. (1996) Human Gene Therapy 7: 319-331.
Morsy et al. (Nov. 17, 1993) JAMA, vol. 270, No. 19, pp. 2338-2345.
Ronald Crystal (1995) Science, vol. 270, pp. 404-409.
Coghlan (25 Nov., 1995) New Scientist pp. 14-15, vol. 149.
Marshall (Aug. 1995) Science, vol. 269, pp. 1050-1055.
Marshall (Dec. 1995) Science, vol. 270, p. 1751.
Orkin & Moltulsky (Dec. 7, 1995) NIH Report on Gene Therapy.
Sugden et al. (1989) Journal of Virology, pp. 2644-2649.
Zimber-Strobl et al. (1991) Journal of Virology, pp. 415-423.
Perricaudet et al. (1992) Ann Oncol., vol. 3, suppl. 5, p. 135.
Mastrangelo et al (1993) The Journal of Clinical Investigation, vol. 91, pp. 225-234.
Jean Marx (1993) Science, vol. 259, pp. 760-761, Jul. 30, 1996.
Kozarsky et al. (1993) Current Opinion in Genetics and Development, 3, pp. 499-503, Jul. 30, 1996.
Haddada et al. Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment pp. 1-22 1995.
Phelps et al. Analysis or trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism vol. 65 No. 12 1991 pp. 6922-6930.
EBNA2 can activate transcription via E2 factor binding sites pp. 165-168 1993 vol. 225.
Clayman et al., “Adeno p53 Gene Transfer in a Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma,” Soc. for Biol. Therapy, Ann. Meeting, Abstract (1996).
Clayman et al., “Adenovirus Mediated p53 Gene Transfer in a Phase I Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma,” ASCO Annual Meeting, Abstract (1997).
Clayman et al., “Adenovirus Mediated p53 Gene Transfer in Patient with Advanced Recurrent Head and Neck Squamous Carcinoma,” AACR Annual Meeting, Abstract.
Clayman et al., “Gene Therapy for Head and Neck Cancer: Comparing the Tumor Suppressor Gene p53 and a Cell Cycle Regulator WAFI/CIP1(p 21),” Arch. Otolaryngol. Head Neck Surgery, vol. 122, pp. 489-493 (1996).
Coghlan, “New Scientist,” vol. 149, pp. 14-15 (1995).
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,” Science vol. 270, pp. 404-409 (1995).
Dong et al., “Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus,” Human Gene Therapy vol. 7, pp. 319-331 (1996).
Karlsson, “Treatment of genetic defects in hematopoietic cell function by gene transfer,” Blood, vol. 78, No. 10, pp. 2481-2492 (1991).
Kozarsky et al., “Gene therapy: adenovirus vectors,” Current Opinion on Genetics and Development, vol. 3, pp. 499-503 (1996).
Marshall, “Gene therapy's growing pains,” Science, vol. 269, pp. 1050-1055 (1995).
Marshall, “Less hype, more biology needed for gene therapy,” Science, vol. 270, p. 1751 (1995).
Marx, “Cell death studies yield cancer clues,” Science, vol. 259, pp. 760-761 (1996).
Mastrangeli et al., “Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer,” The Journal of Clinical Investigation, vol. 91, pp. 225-234 (1993).
Morsy et al., “Progress toward human gene therapy,” JAMA, vol. 270, No. 19, pp. 2338-2345 (1993).
Orkin & Moltulsky, NIH Report on Gene Therapy, (Dec. 7, 1995).
Roth et al., “Retrovirus-Mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer,” Nature Medicine, vol. 2, pp. 985-991 (1996).
Sugden et al., “A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection,” Journal of Virology, pp. 2644-2649 (1989).
Swisher et al., “Persistant Transgene Expression Following Repeated Injections of a Recombinant Adenovirus Containing the p53 Wild-Type Gene in Patients with Non-Small Cell Lung Cancer,” AACR Annual Meeting, Abstract.
Swisher et al., “Adenoviral Mediated p53 Gene Transfer in Patients with Advanced Non-Small Cell Lung Cancer(NSCLC),” ASCO Annual Meeting, Abstract (1997).
Zimber-Strobl et al., “Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene,” Journal of Virology pp. 415-423 (1991).

Affiliated with

Also associated with

Rating

Recombinant adenoviruses for gene therapy in cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant adenoviruses for gene therapy in cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant adenoviruses for gene therapy in cancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3553717